前苏联专利SU1676454A3 Method for peptides preparation of theirs pharmaceutically accessible salts

专利PDF首页>>前苏联专利

专利附录

专利说明

权利要求

类似技术

同族专利

引用文献

法律状态

优先权

专利摘要:
Compounds of formula (I): <CHEM> (wherein m is 0 or 1 and R<1>-R<5> are a variety of organic groups) have the ability to inhibit the activity of renin and may thus be used to treat hypertension induced by failures in the renin-angiotensin system. They are prepared by conventional peptide synthesis routes.
公开号:SU1676454A3
申请号:SU853987362
申请日:1985-11-28
公开日:1991-09-07
发明作者:Морисава Ясухиро；Ябе Юитиро；Катаока Мицуро；Идзима Ясутеру；Кокубу Тацуо；Хивада Кунио
申请人:Санкио Компани Лимитед (Фирма)；
IPC主号:

专利说明:

The invention relates to a method for producing peptides or their pharmaceutically acceptable salts, new biologically active compounds that can be used in medicine.
The purpose of the invention is a method for producing novel peptide derivatives with low toxicity and higher rennin inhibitory activity.
Example 1. Bis (1-naphthylmethyl) acetic acid.
2.86 g (0.12 mmol) of sodium was dissolved in 250 ml of anhydrous ethanol and 19.95 g (0.12 mmol) of diethyl malonate were added to the solution while cooling with ice. The reaction solution is then stirred for 1 hour, after which 22.00 g (0.12 mmol) of 1-chloromethylnaphthalene is added dropwise and the resulting solution is stirred for 3 hours at room temperature, and then stirred for 3 hours at 50 ° s The salt that separated was filtered out, and the filtrate was concentrated by evaporation under reduced pressure. The residue is purified by medium pressure liquid chromatography on a silica gel column to yield 15.2 g.
(L

WITH
(41.3%) diethyl (1-naphthylmethyl) malonate and 9.8 g (17.8%) diethyl di (1-naphthylmethyl) malata.
9.8 g (22.2 g mmol) of diethyldi (1-naphthylmethyl) malonate are dissolved in 100 ml of a 1: 1 mixture by volume of butanol and water, 10 g of potassium hydroxide are added to the resulting solution and the mixture is heated at boiling under reflux at 150 ° C for 8 hours. The reaction mixture is then concentrated by evaporation under reduced pressure. The residue is mixed with water, and then concentrated hydrochloric acid is added to pH 1. The crystals separated out are filtered to obtain 6.2 g (82%) of the title compound as white crystals with m.p. 172-174 ° C.
Example 2. 2- (1-Naphthylmethyl) -6-phenylhexanoic acid.
1.3 g (57 mmol) of sodium is dissolved in 200 ml of anhydrous ethanol. This solution is mixed with 14.8 g (50 mmol) diethyl (1-naphthylmethyl) malonate under ice cooling and stirred for 1 hour. 11.7 g (55 mmol) of 4-phenylbutyl bromide are then added dropwise and the resulting the mixture is stirred for 6 hours at 50 ° C. The salt that separated was filtered out and the resulting filtrate was concentrated by evaporation under reduced pressure. The residue is purified on a chromatographic column with silica gel (eluted with a mixture of 1: 4 by volume of ethyl acetate and hexane) to obtain 15.4 g (71%) of diethyl- 2- (1-naphthylmethyl) -2- (4-phenylbutyl) malone.
This compound is treated the same. as described in example 1, potassium hydroxide in aqueous butanol to obtain 6.8 g (58%) of the title compound as a colorless oily substance.
Example 3. Diethyl- (1-naphthylmethyl) malonate.
Sodium ethoxide, prepared from 2.3 g (0.1 gram-atom) of sodium, is suspended in 250 ml of dimethylformamide. 16.0 g of diethylmalonate are added with ice-cooling until a suspension is obtained, and the mixture is stirred at 0 ° C for 30 minutes and then at room temperature for 1 hour. To this solution is added 100 ml of dimethylformamide containing 17, 6 g (0.1 mmol) of 1-chloromethyl naphthalene for 2 hours. The mixture is then stirred at room temperature overnight, after which the solvent is distilled off under reduced pressure. The residue is mixed with water and then extracted with ethyl acetate. The ethyl acetate layer was washed with a saturated aqueous solution of sodium chloride, dried over anhydrous sodium sulfate, and concentrated, evaporated under reduced pressure. After evaporation of the residue under reduced pressure, 21.3 g of the title compound are obtained as a colorless viscous liquid with mp. 210 ° C (5 mm Hg, 667 Pa).
Example 4. Diethylbenzyl (1-naphthylmethyl) malonate.
01.05 g (25 mmol) 55% w / w The sodium hydride suspensions in mineral oil are washed three times with anhydrous hexane to dry it, and then mixed with 100 ml of dimethylformamide. To this suspension, 7.21 g (24 mmol) of diethyl (1-naphthylmethyl) malonate are added under ice-cooling. After the evolution of hydrogen ceases, the reaction mixture is stirred for 30 minutes, and then 0.10 g (24 mmol) of benzyl bromide is added and the mixture is stirred for another 2 hours at room temperature. At the end of this time, the reaction mixture is concentrated by evaporation under reduced pressure. The residue is mixed with water and extracted with ethyl acetate. The ethyl acetate layer was washed with a saturated aqueous solution of n trichloride, dried over anhydrous sodium sulfate and
0 is concentrated by evaporation under reduced pressure. The residue was purified by column chromatography on silica gel (eluted with a 15: 1 v / v mixture of hexane and ethyl acetate) to obtain 7.3 g of this
5 Compounds as a colorless oily substance.
Mass spectrum, gp / e: 390 (M1). Example 5. Diethyl 2- (2-megoxyethoxy) ethyl (1-naphthylmethyl) malonate.
0 Repeat the reaction described in Example 4. But using 2.12 g (10 mmol) of 2- (2-methoxyethoxy) ethyl iodide and 2.0 g (6.7 mmol) of diethyl- (1-naphthylmethyl) malonate to give 1, 93 g of the above compound in
5 as a colorless oily substance after purification on a chromatographic column with silica gel (eluted with a mixture of 10: 1 by volume of hexane and ethyl acetate). Mass spectrum, years / e: 402 (M4.
0P p (liter 6. Diethyl 2- (2-benzyloxyethoxy) methyl (1-naphthylmethyl) malonate.
The reaction described in Example 4 is repeated, but 3.98 g (10 mmol) of 2- (2-bzxyloxy-ethoxy) ethyl iodide and 3.0 g are used.
5 (1C mmol) dmztil (1- -; athylmethyl) malonate to obtain 3.62 g of the title compound as a colorless oily substance after purification on a chromatographic column (eluted with an 8: 1 mixture of hexane and ethyl acetate).
Mass spectrum, m / e: 478 (M4).
Example 7. 1-Benzyl-3-naphthylpropionic acid.
A mixture of 7.3 g (18 mmol) diethylbenzyl (1-naphthylmethyl) malonate. 70 ml of butanol, 70 ml of water and 7 g of potassium hydroxide are heated in an oil bath (150 ° C) under reflux for 10 hours. The reaction mixture is cooled and then concentrated by evaporation under reduced pressure, after which it is acidified concentrated hydrochloric acid and extracted with ethyl acetate. The ethyl acetate layer was washed with a saturated aqueous solution of sodium chloride, dried over anhydrous sodium sulfate, and concentrated, evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluted with a 1: 1 v / v mixture of hexane and ethyl acetate) and the resulting solid was recrystallized from a mixture of hexane and ethyl acetate to obtain 3.29 g of the title compound as colorless crystals with mp. 119-120 ° C.
Mass spectrum, m / e: 290 (M).
Example 8. (2-Methoxyethoxy) (1-naphthyl) prog1Ionic acid.
Repeat the reaction described in Example 7, but using 1.87 g (4.6 mmol) of diethyl 2- (2-methoxyethoxy) ethyl (1-naphthyl-methyl) malonate to obtain 1.12 g of the title compound as a colorless oil. - Clean the substance after purification on a chromatographic column with silica gel (eluted with ethyl acetate).
Mass spectrum, m / e: 302 (M).
Example 9. (2-Benzyloxyethoxy) (1-naphthyl) propionic acid.
Repeat the reaction described in Example 7, but using 2.50 g (5.2 mmol) of diethyl 2- (2-benzyloxyethoxy) ethyl (1-naphthylmethyl) malonate to obtain 1.76 g of the title compound as a colorless oil. The substance was purified on a silica gel column chromatography (eluted with ethyl acetate).
Mass spectrum, m / e: 378 (M4).
Example 10. 4 (5) (1-nasg-hydromethyl) acetyl} -1-histidyl-amino} -3 (5) hydroxy-6-methyl-M-2 (5) - (-) - methyl butyl Hepatan1Mid (Compound 1).
The first stage. 4 (5) - (M-Benzyloxycarbonyl-1-histidylamino) 3 (5) -oxy-6-methyl- M- {2 (5} - {-) - methyl 6-butyl heptanamide.
10 ml bn. of a solution of hydrochloric acid in dioxane is added to 0.9 g (2.6 mmol) of (3S, 45) -4-tert-butoxycarbonylamino-3-hydroxy-6-methyl-M-2 (3) - (- ) -methylbutyl heptanamide. Then the reaction mixture is stirred for 20 minutes at room temperature under a nitrogen atmosphere, after which it is evaporated to dryness under reduced pressure. The residue was dissolved in 10 ml of dimethylformamide, and then 0.26 g (2.6 mmol) of N-methylmorpholine was added under ice-cooling to obtain a solution (3S, 45) -4-amino-3-hydroxy-6-methyl -M- {2 (5) - (-) - methylbutyl heptanamide. This solution is added to 10 ml.
0 of a cold solution in dimethylformamide-M-benzyloxycarbonyl-1-histidinazide, prepared from 0.91 g (3 mmol) of N-benzyloxycarbonyl-1-histidine hydrazide by treatment with isopentyl nitrite, and the resulting
5 the mixture is stirred for 5 days at 4 ° C. The solvent was distilled off under reduced pressure, and then a saturated aqueous solution of potassium carbonate was added to the residue, and the mixture was extracted with ethyl acetate. The ethyl acetate extract was washed with a saturated aqueous solution of sodium chloride, dried over anhydrous sodium sulfate, and concentrated, evaporated under reduced pressure. The resulting residue is purified by chromatography on a column of silica gel, eluting with a 20: 1 mixture of chloroform and methanol. The desired fractions are concentrated by evaporation under reduced pressure to obtain a syrupy residue. The syrup is cured by adding diethyl ether, and the residue is collected by filtration, whereby 0.96 g of the title compound is obtained as a white powder, m.p.
5 158-168 ° H.
Calculated,%: C, 62.89; H 8.01; N 13.58.
C27H41N505
Found,%: C 62.73; H 7.94; N 13.67.
The second stage is 4 (5) (1-naphthylmethyl) acetyl -1-histidylamino} -3 (5) -oxy-b-methyl-M-2 (5) - (-) - methylbutyl heptenamide.
The benzyloxycarbonyl group is removed from the compound obtained in the first stage by treating it with hydrogen at room temperature in the presence of 5 May% w / w. to palladium on activated carbon. 91 mg (0.2 mmol) of the obtained compound. 66.5 mg (0.2 mmol) bis (1-naphthylmethyl) acetic acid and 39.4 mg (0.22 mmol)
The 0M-hydroxy-5-norbornene-2,3-dicherboxyimide is dissolved in a mixed solvent consisting of 1 ml of dimethylformamide and 6 ml of methylene chloride. and the resulting solution is cooled on ice. To the resulting solution
5, 44 mg (0.4 mmol) of N-methylmorpholine and 45.4 mg (0.22 mmol) of dicyclohexyl-carbodiimide are added in this order and the mixture is stirred for 1 hour under ice-cooling, and then for 10 days at room temperature The separated dicyclohexyl urea is filtered off and the filtrate is condensed to evaporate under reduced pressure. To the resulting residue is added 5% by weight of an aqueous solution of sodium bicarbonate. The oily substance that is separated out is extracted with ethyl acetate. The organic extract is washed with a saturated aqueous solution of sodium chloride, dried over anhydrous sodium sulphate and concentrated, evaporated under reduced pressure. The residue obtained is purified by silica gel column chromatography using a mixture of 10: 1 by volume of chloroform and methanol as eluent. The desired fractions are collected and concentrated by evaporation under reduced pressure. The residue is solidified by adding diethyl ether, and the resulting solid is collected by filtration to obtain 35 mg of the title compound as a pale yellow powder, m.p. 130-15 ° C.
  -66 ° (With 0.1, meganol). Calculated,%: C 71.54; H 7.68; N 9.70. C43H53M504 H20
Found,%: C 71.78; P7.61; N 10.00.
Salt production.
722 mg (mmol). 4 (5) - {G Ibis (1-naphth1allmethyl) acetyl -1-histilamino} - 3 (3) -oxy-b-methyl-N- 2 (5) -methylbutyl haptanamide monohydrate is dissolved in 30 ml of methanol. 10 ml cold 4 n. hydrochloric acid in dioxane is added to the methanol solution. The solution was evacuated to dry under reduced pressure to obtain 757 mg of the title compound as a white powder.
Example 11. 4 (8) - {M- {Bis (1-naphthylmethyl) acetyl 1-leucylamino} -3 (5) -oxy-6-methyl-M-ethylheptanamide (compound 2).
The first stage. Ethyl-4 (5НМ-tert-butoxycarbonyl-1-lecylamino) -3 (5) -oxy-6-methylheptanoate.
The t-butoxycarbonyl group is removed from 3.06 (10.1 mmol) of ethyl- (35, 4S) -4-tert-butoxycarbonylamino-3-hydroxy-6-meth-ylheptanoate by conventional means (as in the first stage example 10). The product obtained is dissolved in methylene chloride and neutralized with triethylamine while cooling with ice. To the resulting solution, 3.48 g (10.6 mmol) of N-tert-butoxycarbonyl-1-leucine-M-oxysuccinimide was added and the mixture was stirred for 3 hours at room temperature. Then 1.1 ml of 3- (M, M-dimethylamino) -propylamine are added and the resulting mixture is stirred for an additional 1 hour. The reaction solution is concentrated by evaporation under reduced pressure. Ethyl acetate is added to dissolve the residue and the ethyl acetate solution is washed with a 5% w / v aqueous solution of sodium bicarbonate, 10 May. %
volume with an aqueous solution of citric acid and a saturated aqueous solution of sodium chloride in the indicated order. It is then dried over anhydrous sodium sulphate. The solvent is distilled off under reduced
0 pressure and the resulting residue is recrystallized from a mixture of diethyl ether and hexane to obtain 3.02 g of the title compound as a pale red powder, m.p. 113-114 ° C.
5Calculated,%: C 60.55; H 9.68; N 6.73.
C21H / 10N206
Found,%; C, 60.36; H 9.70; N 6.66. Stage 2, 4 (5) - (M-tert-Butoxycarbonyl-1-lecylamino) -3 (5) -oxy-bmethyl0 heptanoic acid hydrazide.
2.65 g (6.36 mmol) of the compound synthesized in the first stage and 3.19 g (63.7 mmol) of hydrazine monohydrate are dissolved in 80 ml of dimethylformamide and the resulting
5, the mixture was stirred at room temperature for 19 hours, and then another 12.5 hours at 50 ° C. The reaction solution is concentrated by evaporation under reduced pressure. Water and ethyl acetate are added to the residue. The isolated insoluble product is filtered off. The filtrate was washed with water and then dried over anhydrous magnesium sulphate. The solvent is distilled off under reduced pressure. Remainder
5 and the insoluble product that was isolated during filtration was combined and suspended in boiling diethyl ether. The isolated compound was collected by filtration and dried to give 1.73 g of the indicated compound as colorless prisms, m.p. 140-147 ° C.
Third stage. 4 (5) - (M-tert-Butoxycarbonyl-1-lzycylamino) -3 (5) -oxy-b-methyl-N-these l heptane m.
5 402 mg (1.00 mmol) of the compound synthesized in the second stage are dissolved in 8 ml of dimethylformamide, and the resulting solution is cooled to -60 ° C. 0.62 ml of 6N solution is added to the cooled solution.
0 hydrochloric acid in dioxane and 0.18 ml (1.35 mmol) of isopentyl nitrite and the resulting solution is stirred for 10 min at -2 ° C, then cooled again to -60 ° C. Then the solution is neutralized by adding 0.61
5 g of N-methylmorpholine, after which 108 mg (1.32 mmol) of ethylamine hydrochloride are added and the reaction mixture is stirred at 5 ° C for 20.5 hours. The reaction mixture is then taken up in water and the mixture is extracted with ethyl acetate. The ethylacetate phase is washed on 5 May. % volume aqueous sodium bicarbonate solution, 10 May. % / volume of an aqueous solution of citric acid and a saturated aqueous solution of sodium chloride in this order, and then dried over anhydrous magnesium sulfate. The solvent is distilled off under reduced pressure. The residue is washed with hexane, collected by filtration, and dried to give 345 mg of the title compound as a white powder, m.p. 193-197 ° C. Calculated,%: C 60.69; H 9.94; N 10.11.
C21H / MN305
Found,%: C 60.46; H 10.04; N 10.13.
The fourth stage. 4 (5) (1-naphthylmethyl) acetyl -1-leucylamino} -3 (5) - ox-6-methyl-M-ethylheptanamide.
The tert-butoxycarbonyl group is removed from 99 mg (0.24 mmol) of the compound obtained in the third step. The product obtained is dissolved in dimethylformamide. To the resulting solution were added 91 mg (0.24 mmol) of bis (1-naphthylmethyl) acetic acid, 50 mg (0.28 mmol) of 90% diethylphosphorocyanidate and 64 mg (0.63 mmol) of triethylamine under ice-cooling. and the resulting mixture is stirred for 14.5 hours at room temperature. The reaction solution is sequentially treated as described in Example 10 (second step), and the product obtained is recrystallized from a mixed solvent consisting of methylene chloride and hexane, to obtain 59 mg of the title compound as colorless needles, m.p. 93-96 ° C.
  -157 ° С (С 0.1, methanol).
Calculated,%: C 75.32; H 8.06; N 6.59.
C4oH5iN304 1 / 2H20
Found %: C 75.06; H 8.08; N 6.60.
Example 12. 4 (5) (1-naphthylmethyl) ecetyl -1-lecylamino} -3 (5) -oxy-6-methyl-M- (2-methylbutyl) heptanamide (compound 3).
The first stage. 4 (5) - (1-tert-Butoxycarbonyl) -1-leucylemino) -3 (5) -oxy-6-methyl-M- (2-X-methylbutyl) heptanamide.
344 mg (1.23 mmol) of (35, 45) -4-amino-3-hydroxy-6-methyl-M- (2-methylbutyl) hepta.zhamide monohydrochloride are dissolved in methipenchloride. This solution is neutralized with triethylamine under ice-cooling, and then 420 mg (1.28 mmol) of M-tert-6-oxycarbonyl-1-leucine M-oxysuccinimide are added to it. The resulting mixture was stirred for 22.5 hours at room temperature, and then 0.2 ml of 3- (M, 1, 1-dimethyl-mmno) propylamine was added and the resulting mixture was stirred for another 1 hour. Then the reaction
the solution is concentrated by evaporation under reduced pressure. Methylene chloride is added to the residue and the resulting solution is washed with 5% w / v aqueous solution of sodium bicarbonate, 10% w / v aqueous solution of citric acid and saturated sodium bicarbonate in that order, and then dried over anhydrous magnesium sulphate. The solvent is distilled off under reduced pressure. The resulting residue was washed with ethyl acetate, filtered and dried to obtain 328 mg of the title compound as a white powder, m.p. 166-168 ° C.
Calculated. %: C, 62.99; H 10.35; N 9.18.
C24H47N305
Found,%: C 62.92. H 10.16; N 9.14.
The second stage. 4 (5) - {M- {Bis (1-naphthylmethyl) acetyl -1-lecylamino} -3 (5) - hydroxy-b-methyl-M- (2-methylbutyl) heptanamide.
The tert-butoxycarbonyl group is removed from 100 mg (0.22 mmol) of 4 (5) - (M-tert-butoxycarbonyl-lecylamino) -3- (3) -oxy-6-methyl-M- (2- methylbutyl) heptsnamide, obtained in the first stage, and the product obtained is dissolved in dimethylformamide. 77 mg (0.23 mmol) bis (1-naphthylmethyl) acetic acid was added to this solution. 42 mg (0.23 mmol) of 90% di-ethyl phosphorocyanic acid and 52 mg (0.54 mmol) of triethylamine are cooled with ice and the mixture is stirred for 4 hours at room temperature. Then the reaction solution is concentrated by evaporation under reduced pressure. Ethyl acetate is added to the residue and the resulting solution is washed with 5% w / v aqueous solution of sodium bicarbonate, 1N. hydrochloric acid and saturated aqueous solution
sodium chloride in this order, after which it is dried over anhydrous magnesium sulphate. The solvent is distilled off under reduced pressure, and the resulting residue is recrystallized from a mixed solvent consisting of methylene chloride and hexanes. to obtain 40 mg of the title compound as a white powder, m.p. 98-100 ° C.
--143 ° (C 0.1, methanol). Calculated,%: C, 74.96; H 8.49; N 6.10. C43H57N304 1/2 H20 Found: C, 75.10; H 8.56; N 6.10.
Example 13. 4 (5) - {Y-bis (1-naphthylmethyl) acetyl -1-lecylamino} 3 (5) - hydroxy-6-methyl-M- (2-ethoxyethyl) heptanamide (compound 4) .
The first stage. 4 (5) - (M-tert-Butoxycarbonyl-1-leucylamino) -3 (5) -oxy-6-methyl-N- (2-ethoxymethyl) heptanamide.
The tert-butoxycarbonyl group is removed from 539 mg (1.56 mmol) (35, 45) -4-tert-butoxycarbonylamino-3-hydroxy-6-methyl-M- (2-ethoxyethyl) heptanamide in the usual way, and then the resulting product dissolved in methylene chloride with ice cooling, and neutralized with triethylamine. To this solution, 534 mg (1.63 mmol) of N-tert-butoxycarbonyl-1-leucine-N-oxysuccinimide was added and the reaction mixture was stirred at room temperature for 22 hours. Then 0.2 ml of 3- (M, M-dimethylamino) propylamine and the resulting mixture is stirred for another 1 h
The reaction solution is concentrated by evaporation under reduced pressure. Methylene chloride is added to the residue and the polished solution is washed with 5% w / v aqueous sodium bicarbonate solution, 10% w / v aqueous solution of citric acid and saturated sodium chloride solution in this order, and then dried over anhydrous sulphate - neither. The solvent is distilled off under reduced pressure. The residue obtained is recrystallized from a mixed solvent consisting of methylene chloride and ethyl acetate to obtain 294 mg of the title compound in the zid of colorless needles, m.p. 172-173 ° C.
Calculated,%: C 60,10; H 9.87; N 9.14
C23H45N306
Found,%: C 59.99; H 9.96; N 9.09.
The second stage. 4 (5) (1-nzfthylmethyl) acetyl -1-lecylamino} -3 (5) -oxy-6-methyl-Shch2-ethoxyethyl) heptanamide.
The tert-butoxycarbonyl group is removed from 105 mg (0.23 mmol) 4 (5) - (L-tert-butoxycarbonyl-1-lecylamino) -3 (5) -oxy-6-methyl-M- (2- ethoxyethyl) heptanamide in the usual way, and then the product obtained is dissolved in dimethylformamide. 78 mg (0.23 mmol) of bis (1-naphthylmethyl) acetic acid, 43 mg (0.24 mmol) of 90% diethylphosphoric acid and 50 mg (0.49 mmol) of triethylamine are added to this solution while cooling with ice and the resulting mixture is stirred for 5.5 hours at room temperature. The reaction solution is treated as in the second stage of Example 12, and the product obtained is recrystallized from a mixed solvent consisting of methylene chloride and diethyl ether, in order to obtain 58 mg of the indicated compounds as colorless needles, mp. 168-169 ° C.
  -168 ° (C 0.1, methanol). Calculated,%; C, 73.98; H 8.13 N 6.16.
C42H55N305
Found,%: C 73.85; H 8.24: N 6.14. Example 14. 4 (5) (1-naphthylmethyl) acetyl -1-leucylamino) -3 (5) -oxy-6-me- (3,4-dimethoxyphenethyl) heptanamide
(compound 5).
The first stage. 4 (5) - (M-tert-Butoxycarbonyl-1-lecylamino) -3 (5) -oxy-6-methyl-N- (3,4-dimethoxyphenethyl) heptanamide.
0.74 g (1.7 mmol) of (3S, 45) -4-tert-butok0 of sycarbonyl-amino-3-hydroxy-6-methyl-L- (3,4-d. Methoxyphenethyl) heptanamide is dissolved in 8 ml 6 n. solution of dioxane and the resulting reaction mixture after stirring for 20 minutes at
5 at room temperature is evaporated to dryness under reduced pressure. The residue was dissolved in 20 ml of methylporide and, with ice-cooling, the resulting solution was neutralized by adding 0.24 ml of triethylamine. Then, 0.58 g (1.8 mmol) of tert-butoxycaropyl-1-leucine-P -oxy succinimide dissolved in 5 ml of methylene chloride is added. The reaction mixture is stirred for 20 hours at room temperature.
5 temperature, after which 0.2 ml of 3- (M, M-dimethylamino) propylamine is added to the mixture and the reaction mixture is stirred for another 1 hour. The reaction solution is concentrated by evaporation under reduced pressure.
0 pressure, and then water and ethyl acetate are added to the resulting residue. The residue that separated was filtered out and the organic layer was collected. This organic layer was washed with a 10% w / v aqueous solution of citric acid. On a 5% w / v aqueous solution of sodium bicarbonate and a saturated aqueous solution of sodium chloride in this order, and then dried over anhydrous magnesium sulphate. The solvent is distilled off under reduced pressure. The residue and precipitate are filtered off as described, combined and crystallized from a mixed solvent consisting of methylene chloride and ethyl acetate, to half an exercise of 0.69 g of the indicated compound as colorless needles, mp. 192-193 ° C.
Calculated,%: C 63.13; H 8.95; N 7.62.
C29NadZizot
Found,%: C 63.06; H 8.83; N 7.56.
0The second stage. 4 (5) (1-naphthylmethyl) acetyl-L-lecylamino} -3 (5) -oxy-6-methyl - (3,4-d / 1 methoxy-phenethyl) heptanamide.
153 mg (0.28 mmol) 4 (5) - (M-tert-butoxy-krbonyl-α-lecylamino) -3 (5) -oxy-6-methyl 5-M- (3,4-dimethoxyfecethyl) heptenamide is dissolved in 1.4 ml 5 n. EZ dioxins hydrochloric acid solution is stirred for 20 minutes at room temperature and then evaporated to dryness under reduced pressure. Remainder
dissolved in 3 ml of dimethylformamide and stirred while cooling with ice. To this solution were added 93 mg (0.27 mmol) of bis (1-naphthylmethyl) acetic acid, 49 mg (0.7 mmol) of 90% diethylphosphorocyananate and 59 mg (0.58 mmol) of triethylamine and the reaction mixture stirred for 1 h while cooling with ice, and then stirred for another 3 h at room temperature. Then the reaction solution is concentrated by evaporation under reduced pressure. Ethyl acetate was added to the residue, and the resulting solution was washed with 5 May. % / volume of an aqueous solution of sodium bicarbonate. 1N hydrochloric acid and a saturated aqueous solution of sodium / urida in this order and dry us with anhydrous magnesium sulfate. The solvent is distilled off under reduced pressure. The residue is washed with hexane and then crystallized from a mixed solvent consisting of methylene chloride and diethyl ether to obtain 128 mg of the title compound as a white powder, m.p. 164-166 ° C.
a 23--104 ° (C 0.1, methanol).
Calculated,%: C, 74.49; H 7.68; N 5.43.
С4вНмГМзОб
Found,%: C 74.32; H 7.63; N 5.44.
Example 15. N 4 (5) (1-naphthyl-megyl) acetyl -1-norleycylamino} -3 (5) -ox- and 6-methylhepteno-1-isoleucinol (compound 6).
The first stage. (5) -M-tert-Butoxy-carbonyl-nor-leucylamino-3 (5) -oxy-6-methylheptanoyl -1 -isoleucine.
375 mg (1 mmol) (5) - (M-tert-butoxycarbonylamino-3 (5) -oxy-6-methyl heptane L of isoleucinel is treated with 6N, a solution of hydrochloric acid in dioxane to remove the tert-butoxycarbonyl group and get (3S, 45) -4-amino-3-hydroxy-6-methyl-geltanoyl-1-isoleucine hydrochloride. 231 mg (1 mmol) M-tert-butoxycarbonyl-L-norleucine and 135 mg (1 mmol) 1-hydroxybenzene - riazole is added to this compound and the mixture is dissolved in 5 ml of dimethylformamide. 101 ml (1 mmol) of triethylamine are added under ice-cooling and 206 mg (1 mmol) of dicyclohexylcarbodiimide and the reaction mixture. the mixture is stirred for 1 h at 0 ° C, s then overnight at room temperature, water is added, the reaction mixture is extracted with diethyl ether and the insoluble residue is filtered off, the organic extract is washed with 1C-may.% / vol. aqueous citric acid solution , 5% w / v aqueous solution of sodium bicarbonate and saturated aqueous solution of sodium chloride in this order, and then dried over anhydrous sodium sulphate. This solution is concentrated by evaporation under reduced pressure, and then reprecipitated,
adding a mixture of diethyl ether and hexane to obtain 330 mg of the title compound as a white powder, m.p. 139-144 ° C. The second stage. (5) (1-naphthylmethyl) acetyl -1-norlecyamino} -3 (5) 0 hydroxy-6-methylheptanoyl) -1 -isoleucine.
163 mg (0.33 mmol) (ZNM-tert-butoxycarbonyl-and-neu-leolecylamino) -H (3) - hydroxy-6-methylheptanoyl -1 -isoleucinol is treated in the same way as in the second stage
5 of Example 12, to obtain 110 mg of the title compound as a white powder, m.p. 135-138 ° C.
  -124 ° (C 0.1, meta tol).
Calculated,%: C 73.81; H 8.40; N 5.87. .
С-мНбэМзОб 1/3 Н20
Found,%: C 73.92; H 8.36; N 5.94.
Example 16. (5) (1-naphthyl-methyl) acetyl-β-histidilemino} - 3 (5) -oxy-6-methylheptanoyl -1-isoleucinol
0
five
0
(compound 7).
749 mg (2 mmol) of 4 {5) -M-tert-butoxycarbonylemino) -3 (5) -oxy-6-methylheptanoyl -1 -isoleucinel are treated with 6N hydrochloric acid in dioxane to remove the tert-bugoxycarbonyl group and obtaining (S, 45) -4-amino-3-hydroxy-6-methylheptanoyl -1 -isoleucine hydrochloride. To this compound, 819 mg (2 mmol) of n-tert-butoxycarbonyl-Mt-tosyl-L-histidine and 359 mg (2.2 mmol) of diethylphosphorocyanide, are added, the whole mixture is dissolved in 10 ml of dimethylformamide. Under ice-cooling, 425 ml (4.2 mmol) of triethylamine was added dropwise to the reaction mixture, and then everything was stirred for 1 hour at 0 ° C and then overnight at room temperature. This reaction mixture is concentrated by evaporation under reduced
0
five
0
five
pressure, and the residue is mixed with ethyl acetate. An ethyl acetate solution is washed 10 May. % / volume of an aqueous solution of citric acid, 5 May. The% / vol. aqueous solution of sodium bicarbonate and saturated aqueous sodium chloride solution in this order, dried over anhydrous sodium sulfate and concentrated, evaporated under reduced pressure. The oily residue is treated with trifluoroacetic acid in the presence of anisole to remove the t-butoxycarbonyl group and give 4 (5) - (1 Pt-tosyl-1-histidyl amine) -3 (5) -oxy-6-methylhepanoyl- | -isoleucine rifluoroacetate.
120 mg (0.35 mmol) of bis (1-naphthylmethyl) acetic acid and 60 mg (0.35 mmol) of diethylphosphorocyanidate are added to this compound and the entire mixture is dissolved in 2.5 ml of dimethylformamide. 70 mg (0.67 mmol) of triethylamins are added dropwise under ice-cooling to the reaction mixture, which is stirred for 1 hour at 0 ° C. Then the reaction mixture is concentrated by evaporation under reduced pressure, and the residue is mixed with ethyl acetate. The ethyl acetate solution is washed on 10 May. % v / v citric acid solution, 5% w / v aqueous solution of sodium bicarbonate and saturated aqueous solution of sodium chloride in this order, dried over anhydrous sodium sulphate and concentrated, evaporating under reduced pressure. 170 mg (1.28 mmol) of 1-hydroxybenzotriazole are added to the residue, the mixture is dissolved in 5 ml of tetrahydrofuran. Then this reaction mixture was stirred at room temperature overnight, after which it was concentrated by evaporation under reduced pressure. The residue is mixed with ethyl acetate. An ethyl acetate solution is washed 5 May. The% / vol. aqueous solution of sodium bicarbonate and saturated aqueous solution of sodium chloride in this order is dried over anhydrous sodium sulfate and concentrated, evaporating under reduced pressure. The residue was purified by silica gel thin-layer chromatography (using an 8: 1 by volume mixture of chloroform and methanol as a developing solvent) to obtain 38.8 mg of the title compound as white crystals, m.p. 175-179 ° C.
  -70 ° (With 0.1, methanol). Calculated,%: C 69.45; H 7.68; N 9.20.
C44H55N505 1.5H20
Found,%: C 69.34; H 7.38; N 8.78.
Example 17. ((1-Naphthyl-methyl) acetyl-a-methionylamino} -3 (5) -oxy-6-methylheptanoyl - -isoleucine (compound 8J.
The first stage. (8) - (M Fet-Butoxy-carbonyl-1-methionylamino) -3 (5) -oxy-6-methylheptanoyl -1 -isoleucine.
2 ml 6 n. a solution of hydrochloric acid in dioxane is added to 749 mg (2 mmol) of N- and HM-tert-butoxycarbonylemino 3g) - hydroxy-6-methylheptanoyl -1 - isoicinol. Then the reaction solution is stirred for 2 hours at room temperature. and then concentrated by evaporation under reduced pressure. Then 500mg (2 mmol) of tert-butoxycarbonylmethionine and 270 mg (2 mmol) of 1-hydroxybazotriazole are added to the residue. The resulting reaction mixture was dissolved in 30 ml of dimethylformamide, and then 412 mg (2 mmol) of dicyclohexylcarbodiimide was added and the mixture was stirred for 3 hours at 40 ° C. At the end of this time, the reaction mixture is poured into ice water and extracted with ethyl acetate. The insoluble residue is filtered off. An ethyl acetate extract washed 10 May. % / volume aqueous solution of citric acid, 10% w / v aqueous solution of sodium bicarbonate and saturated
an aqueous solution of sodium chloride in that order, and then dried over anhydrous sodium sulphate. This solution is concentrated by evaporation under reduced pressure, and then the residue is precipitated by adding
a mixture of chloroform and hexane, whereby 600 mg of the title compound are obtained as a white powder.
The second stage. (5) - {Ы (Bis (1-naphthylmethyl) acetyl -1-methionylamino) -3 (5) -oxy6-methylheptanoyl -1 -isoleucinol.
2 ml 6 n. a solution of hydrochloric acid in dioxane is added to 600 mg (1.19 mmol) of isoleucinol obtained in the first stage. The mixture is stirred for 2 hours.
at room temperature, and then the resulting solution is concentrated, evaporated under reduced pressure. To the residue were added 403 mg (1.19 mmol) of bis (1-naphthylmethyl) acetic acid and the resulting
the mixture is dissolved in 20 ml of dimethylformamide. With ice-cooling, 300 mg (1.84 mmol) of diethylphosphorocyanidate and 2 ml of triztilamine are added with stirring. The mixture is left to react in
Testing for 1 hour at 40 ° C and then poured into ice water and extracted with ethyl acetate. The ethyl acetate solution is washed with 10% w / v aqueous solution of citric acid, 10 May. % / volume of an aqueous solution of sodium bicarbonate and a saturated aqueous solution of sodium chloride in this order. The extract is then purified by preparative thin layer chromatography (using a mixture of chloroform and methanol as the developing solvent) and the active fraction is precipitated by adding a mixture of chloroform and hexane, resulting in 520 mg of the title compound as a white powder, m.p. 76-.
80 ° C.
I23 -133 ° (C 0.1. Methanol). Example 18. M- {4 (5CHCHBis (1-naphthylmethyl) acetyl-3- (4-thiazolyl) alenylamino} -3 (5) -oxy-6-methylheptanoyl - -izol - neytsinol (compound 9).
The first stage. Methyl ester (1-naphthylmethyl) acetyl-3- (4-ty-) -0. -Alanine,
511 mg (1.50 mmol) of bis (1-naphthylmethyl) in “-acetic acid v 389 mg (1.50 mmol) of methyl 3- (4-thiazolyl) ester — DL-alanine dihydrochloride are suspended in 20 ml of anhydrous tetrahydrofuran, 0 25 ml (1.65 mmol) of diethylphosphorocyanidate and 0.69 ml (4.95 mmol) of triethylamine under ice cooling are then added to this suspension and the studied mixture is stirred overnight at room temperature under nitrogen. At the end of this time, the solvent was distilled off under reduced pressure, and the resulting residue was purified on a chromatographic column with silylikal (eluted with a mixture of 2: 1 by volume of ethyl acetate and hexane) to obtain 630 mg of the indicated compound. 110-112 ° C .
The second stage. (1 -Nzftilmetil) acetyl; l -3- (4-thiazolyl) -DL-alanine hydraulically
620 mg (1.22 mmol) of methyl (1-nefthylmethyl) cetyl-3- (4-t-l-ezolyl) methyl complex. 1 Nina is dissolved in 8 ml of anhydrous dimethylformamide. This pore solution is mixed with 310 mg (6.19 mmol) of hydrazitnehydrate, stirred for 5 hours at 40 ° C. The solvent is distilled off under reduced pressure, and water is added to the residue. The precipitated crystals are collected by filtration, washed with a mixed solvent of hexane and diethyl ether, and dried to obtain 408 mg of the title compound, m.p. 118-121 ° C.
Third stage. (3) (1-naphthyl-megyl) acetyl-3- (4-thiazolyl) alanylamino} -3 (5) -oxy-6-methyl-hepanoyl - -izol - neucinol.
393 mg (0.77 mmol) (1-naphthylmethyl) acetyl-3- (4-thiazolyl) -01-alaninghydrazide are suspended in 10 ml of anhydrous dimethylformamide. To this suspension, at -60 ° C, 0.66 ml of 4N hydrochloric acid tj dioxane solution is added, and then the temperature of the reaction mixture is raised to -20 ° C. This suspension is mixed with 0.13 ml (0.97 mmol) of isopentyl alcohol and stirred for 10 min. After the disappearance of the hydrazide has been confirmed, the temperature of the reaction of thoooo is reduced to -60 ° C. To neutralize, add 0.33 ml (3.00 mmol) of N-methyl morphopine. and then 328 mg (1.02 mmol) of N- (35, 45) -4-ami | 0-3-hydroxy-6-methyl-heptsmoyl -1 -iguleycinol hydrochloride and
0.12 mg (0.09 mmol) of N-methylmorphslin and the reaction mixture is stirred overnight at 4 ° C. The solvent was distilled off under reduced pressure, and the residue was purified by flash chromatography on silica gel (using a 10: 1 mixture of chloroform and methanol as a developing solvent) to obtain 310 mg of the title compound as white crystals, m.p. 94-98 ° C.
Example 19. (5H2 (K8HBis (1-naphthylmethyl) acetyl aminononanoyl) -amino-3 (5) -oxy-6-methylheptanoyl -1.-isoleucinol (compound 10).
3 ml 6 n. A solution of hydrochloric acid in dioxane is added to 58.6 mg (0.156 mmol) of (5) -tert-butoxycarbonylamino-3 (5) -o-si-6-methylheptanoyl - L-isoleucinol. The reaction solution is stirred for 30 minutes at room temperature and then evaporated to dryness under reduced pressure. The residue was dissolved in 2 ml of dimethylformamide, and then, under ice-cooling, 77.5 mg (0.156 mmol) of 2- (P5) (1-naphthylmethyl) acetyl amino acid and 27.9 mg (0.17 mmol) of diethyl was added. - Phosphoric cyanidate. To the reaction mixture, 33 ml (0.327 mmol) of triethylamine was added dropwise and the resulting mixture was stirred for 3.5 hours at room temperature and then concentrated, evaporating under reduced pressure. The residue is mixed with 2 ml of water and extracted with ethyl acetate. The organic layer is dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue is purified by preparative thin-layer silica gel homatography (developing agent 10: 1 by volume of a mixture of chloroform and methanol) to obtain 21.0 mg of the title compound as a colorless powder, m.p. 75-78 ° C.
Example 20 ((1-naphthyl-methyl) acetyl-O-propargylglycylamino} -3 (S) -o x and-6-methylheptaine l-L-isol-ucinol (compound 11).
10 ml 6 n. a solution of hydrochloric acid in dioxane is added to 749 mg (2 mmol) of N-4 (5) -t-6-oxycarbonylamino-3 (5) -oxy-6-methylheptanoyl - L-isoleucinol. The solution is stirred for 30 minutes at room temperature and then evaporated to dryness under reduced pressure. The residue is dissolved in 20 ml of dimethylformamide, and then 426 mg (2 mmol) of N-tert-butox and carbon and l-01 g of propargyl glycine and 270 mg (2 mmol) of 1-hydroxybenzotriazole are added. To this solution, 412 mg (2 mmol) of dicyclohexylcarbodiimide and 1 ml of tr-thylamine are added under ice-cooling. The resulting mixture is stirred for 2 hours at 40-50 ° C, after which the excreted dicyclo re-xyl urine is filtered off. The resulting filtrate is mixed with ethyl acetate, washed with water, 10% w / v sodium bicarbonate solution and saturated aqueous sodium chloride solution in this order, and then the organic layer is dried over anhydrous magnesium sulphate. The solvent is then distilled off under reduced pressure. The residue is mixed with diethyl ether, and the precipitated precipitate is filtered off. The filtrate is evaporated to dryness under reduced pressure. To the residue was added 10 ml of 6N. solution of hydrochloric acid in dioxane and after stirring for 30 minutes at room temperature, the solution is evaporated to dryness under reduced pressure. The residue is dissolved in 20 ml of dimethylformamide, to which 680 mg (2 mmol) of bis (1-naphthylmethyl) acetic acid and 543 mg (3 mmol) of diethylphosphorocyanidine are added. To that
1 ml of triethylamine was added to the solution with stirring. The resulting solution was stirred for 2 hours at 40-50 ° C, poured into ice-cold water and extracted with ethyl acetate. The ethyl acetate layer is washed with a 10 wt.% / Volume aqueous citric acid solution, 5 May. % / vol. aqueous solution of sodium chloride in this order, and then the organic layer was dried over anhydrous sodium sulfate. The solvent is distilled off under reduced pressure, then purified by preparative thin layer chromatography (a developing solvent, ethyl acetate), resulting in the formation of two isomers of this compound, due to the asymmetric carbon atom in the propargyl glycyl fragment, mp. 182-188 and 92-94 ° C, respectively.
Example 21. (5) (1-naphthylmethyl) acetyl -1-leucylamino} -3 (5) - hydroxy-b-methylheptanoyl amino-1-benzyl piperidine (compound 12).
The first stage. 4- (3S, 45) -4-tert-Butoxy-car-non-amino-3-hydroxy-6-methylheptanoyl a-min-1-benzylpiperidine.
348 mg (1.83 mmol) of 4-amino-1-benzylpyridine, 510 mg (1.85 mmol) (3S, tert-butoxycarbonylamino-3-hydroxy-6-methylheptanoic acid, and 358 mg (2.2 mmol) of diethylphosphorocyanocyanidate dissolved in 2 ml of dimethylformamide. To this solution, 223 mg (2.2 mmol) of triethylmine are added dropwise with ice cooling and the mixture is stirred for 30 minutes at 0 ° C and then overnight at room temperature. To the reaction solution
ethyl acetate is added, then washed with 10% w / v aqueous hydrochloric acid, saturated sodium bicarbonate aqueous solution and saturated sodium chloride aqueous solution in this order, dried over anhydrous sodium sulphate and condensed, evaporating at a lower pressure. The resulting residue was purified by silica gel column chromatography (eluted with 20: 1 chloroform and methanol) to obtain 663 mg of the title compound as a slightly yellow glassy substance.
The second stage. (5) - (L-tert-Butoxycarbonyl-b-lecylamino) -3 (5) -oxy-6-methylheptanoyl amino-1-benzylpiperidine.
370 mg (1.60 mmol) M-tert-butoxycarbonyl-α-leucine, 620 mg (1.47 mmol) 4- (3S, 43) -4-amino-3-oxy-6-methylheptanoyl amino- 1 - benzylpiperidine dihydrochloride, obtained by removing the t-butoxycarbonyl group from the compound obtained in the first stage of Example 16, and 313 mg (1.92 mmol) of diethylphosphorocyanidate are dissolved in 2 ml of dimethylformamide. To this solution, 388 ml (3.83 mmol) of triethylamine are added dropwise with ice cooling and the mixture is stirred for 30 minutes at 0 ° C and then overnight at room temperature. Ethyl acetate is added to the reaction solution, then washed with 10% w / v aqueous hydrochloric acid, saturated aqueous sodium bicarbonate solution and saturated aqueous sodium chloride solution in this order, dried over anhydrous sodium sulphate and condensed by evaporation under reduced pressure. The resulting residue is mixed with a solvent (1: 1 by volume, a mixture of ethyl acetate and diethyl ether) and sprayed to obtain 68 mg of the title compound as colorless crystals, m.p. 186-187 ° C.
Calculated,%: C, 66.40; H 9.35; N 9.99.
C31H52N405
Found,%: C 66.33; H 9.38; N 10.04.
Third stage. 4- {4 (5) (1-naphthylmethyl) acetyl -1.-lecylamino} -3 (5) - hydroxy-6-methylheptanoyl amino-1-benzylpiperidine.
213 mg (0.4 mmol) (5) -1-leucylamino-3 (5) -oxy-6-methylheptanoyl amino-1-benzylpiperidiide hydrochloride, obtained by removing the tert-butoxy group from the compound obtained in the second stage of Example 16 , 136 mg (0.4 mmol) of bis (1-naphthylmethyl) acetic acid and 78 mg (0.48 mmol) of diethylphosphorocyanidate are dissolved in 2 ml of dimethylformamide. 146 ml (1.44 ml) are added dropwise to this solution.
mmol) of triethyldmine while cooling with ice and the resulting mixture is stirred at 0 ° C for 30 minutes. then overnight at room temperature. The reaction solution is mixed with ethyl acetate, and it is used on 10 May. % / volume aqueous hydrochloric acid and passes with a valuable aqueous solution of sodium chloride in the specified order, dried over anhydrous sodium sulfate and condensed by evaporation under reduced pressure. The residue obtained is mixed with ethyl acetate and sprayed to obtain 288 mg of the title compound as colorless crystals, m.p. 183-184 ° C.
“-105 ° (C 0.1, MeOH).
/ ngibirovany8 rennina activity.
Biologically tested in which the ability of the compounds to inhibit rennin activity was determined by a method based on the Kokuba method.
Each test compound was dissolved in 60% w / v ethanol. The activity of human rennin in the presence of each compound was measured using sheep oxygen. 1 ml of the test mixture contained 0.1 mol / l phosphate buffer (; H 7.3), human rennin (equivalent to 0.5 ng of angiltensine per ml per minute), sheep angiotensinogenEq equivalent 200 ng of angiotensin 1) . 1x10 M test compound, 6% w / v ethanol and angystenase inhibitors (10 mmol / L sodium ethylenediaminetetraacetate and 3.4 mmol / L 8-hydroxyquinoline). The mixture is allowed to react for 10 minutes at 37 ° C and then the reaction is stopped, the reaction tube is placed in a boiling water bath for 5 minutes. The mixture is then centrifuged and a supernatant (0.05-0.1 ml) is used to analyze the remaining angiotensin 1.
A control experiment was carried out in a similar manner, without using the test compound. From the values obtained, the percent inhibition of rennin activity achieved by each test compound is calculated. The results obtained are presented in the table, which shows the average values of 3 or 4 experiments.
As tests have shown, the described compounds have a higher rennin inhibitory activity than the analog, while they exhibit low toxicity,

权利要求:
Claims (1)
[1]
Invention Formula
Genus vicuna peptide method of general formula
Vg o
R, O
I I
cn he
I I
about
II
fy-CH-C-NH-CH-C-NH-CH-CH-CHj-C-Ej
where RI and R2 are the same and each group
Formula (A) p-Re,
where p 1- A is a C1-C4-alkylene group, Re
- naphthyl group;
0R3 - C1-C-alkyl,% -imidazolylmethyl,
4-thiazolylmethyl or -2- (methylsulfonyl) ethyl;
R4 is an isopropyl group;
RS is a group of the formula NRaRg, where Re
5 hydrogen, Rg — St-C-alkyl group, benzyl-4-piperidnyl group or St-C-alkyl group having a substituent selected from C 1 -C 4 - lkoxy, hydroxy. dimethoxyphenyl and di (C1 C4 alkyl) amino0 RUPP
or their pharmaceutically acceptable salts,
characterized in that the compounds of the formula Ri -CH (R2) -CO (Y-OH 5, where Ri and R2 have the indicated values) are reacted;
Y is a group of the formula -NH-CH (R3) CO, where Yz has the indicated meanings;
g - C or 1,
or reactive derivative of it 0 with a compound of the formula
H (Y) SNH-CH (CH2R 4) -CH (OH) -CH 2CORs where Y has the indicated value; ,one;
and RS have the indicated meanings; 5s + g 1,
and, if necessary, convert any included group within the definitions mentioned to any other such group and target product is isolated in free form or in salt form.
The priority is based on the following signs: 30.11.84 with Ri and R2 are the same or different and each is a group of the formula - (A) p-Nb, where p 1, / C-C4-alkylene; RG - naph- 5 tyl; Pz - Ci-C-alkyl, imidazolylmethyl; R4
isopropyl; RB is NHRg, where Rg is Ci-C / j-alkyl, unsubstituted or substituted by hydroxy, alk (C1-C3) hydroxy.
12/19/84 when RI and R2 are the same or different and each is a group of the formula
- (A) -Yab. where p 1, A - St-C-alkylene; Re - naphthyl; Ra - St-C-alkyl; R4 is isopropyl; RS is NHRg, where Rg is St-C-alkyl, unsubstituted or substituted hydroxy, alk (Cr 5 C4) oxy group, dimethoxyphenyl. di (C1-Sflkylamino group.
01/29/85 when Ri and R2 are the same or different and each is a group of the formula - (A) P-R6. where p 1: A - Ci-C3 alkylene PB.
naphthyl; R3 is 5-imidazolylmethyl. 4- {1,3-thiazolyl) methyl; R4 isopropyl; R5 NHRg, where R9 is C1 C4 alkyl, unsubstituted or substituted by a hydroxy group or a lower alk (C 1 -C 4) hydroxy group.
Editor O. Yurkovetska Tehred M. Morgenthal
Order 3017 Circulation 228. Subscription
VNIIPI State Committee for Inventions and Discoveries at the State Committee on Science and Technology of the USSR 113035, Moscow, Zh-35, 4/5 Raushsk nab.
Production and Publishing Combine Patent, Uzhgorod, Gagarin st., 101
Corrector m- Sharoshi

类似技术:

公开号 | 公开日 | 专利标题

SU1676454A3|1991-09-07|Method for peptides preparation of theirs pharmaceutically accessible salts

US4384994A|1983-05-24|Renin inhibitory peptides

SU1739852A3|1992-06-07|Method for synthesis of peptides or their pharmaceutically acceptable salts

US4738803A|1988-04-19|Amino acid derivatives and their use as antidepressives and hypotensive agents

EP0797447B1|2004-03-03|Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides

US5045537A|1991-09-03|Hydrophilic renin inhibitors, their preparation and use

RU2024549C1|1994-12-15|Glycine derivatives or their physiologically acceptable salts showing capability to inhibit fibrinogen binding in fibrinogen platelet receptor

KR890003603B1|1989-09-27|Process for preparing renin inhibitors containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues

CA1254699A|1989-05-23|Renin inhibitors containing statine or derivativesthereof

DE69432573T2|2004-01-08|Endothelin converting enzyme inhibitors

AU599367B2|1990-07-19|Novel amino acid derivatives

SU1085505A3|1984-04-07|Process for preparing tripeptides

JP3176619B2|2001-06-18|Aromatic sulfonamide compound, inhibitor and pharmaceutical composition containing the same

WO1993018060A1|1993-09-16|New anticoagulant peptide derivatives and pharmaceutical compositions containing the same as well as a process for the preparation thereof

US4656269A|1987-04-07|Histidine derivatives

PL194560B1|2007-06-29|Compounds with growth hormone releasing properties

HU205770B|1992-06-29|Process for producing renin inhibiting dipeptide derivatives and pharmaceutical compositions comprising same

KR19980086989A|1998-12-05|Substituted 6- and 7-amino-tetrahydroisoquinoline carboxylic acids

RU2106356C1|1998-03-10|Pseudopeptides of salts thereof, methods of preparation thereof, and pharmaceutical composition

WO1997049668A1|1997-12-31|Inhibitiors of cysteine protease

EP0206807A2|1986-12-30|Novel amino acid derivatives

EP0252727A1|1988-01-13|Novel amino acid derivatives

US4490386A|1984-12-25|Phosphate salts of 1-[2-[|-amino]-1-oxoalkyl]octahydro-1H-indole-2-carboxylic acids, preparation of, and medical compositions thereof

SE452318B|1987-11-23|AMINO ACIDS FOR USE AS INTERMEDIATES IN THE PRODUCTION OF BESTATIN

同族专利:

公开号 | 公开日

FI854747A0|1985-11-29|

NO854825L|1986-06-02|

KR860004080A|1986-06-16|

HUT39463A|1986-09-29|

KR910001721B1|1991-03-22|

EP0186977A3|1987-09-16|

EP0186977A2|1986-07-09|

ES549457A0|1987-12-01|

ES8800958A1|1987-12-01|

FI854747A|1986-05-31|

DK554685D0|1985-11-29|

DK554685A|1986-05-31|

引用文献:

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

US4070458A|1974-02-28|1978-01-24|Sanraku-Ocean Co., Ltd.|Novel physiologically active peptide and its n-acyl derivatives and processes for producing thereof|

KR870005013A|1985-11-29|1987-06-04|가와무라 요시부미|Lenin-inhibiting oligopeptides, methods of making and uses thereof|

DE3601248A1|1986-01-17|1987-07-23|Hoechst Ag|SUBSTITUTED 4-AMINO-3-HYDROXYBUTTERIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THESE AGENTS AND THEIR USE|

DE3610593A1|1986-03-29|1987-10-01|Hoechst Ag|SUBSTITUTED 4-AMINO-3-HYDROXYBUTTERIC ACID DERIVATIVES METHOD FOR THE PRODUCTION THEREOF, THE CONTAINERS THEREOF AND THEIR USE|

US4895834A|1986-12-15|1990-01-23|Warner-Lambert Company|Renin inhibitors III|

US4735933A|1986-12-15|1988-04-05|Warner-Lambert Company|Renin inhibitors III|

EP0274259B1|1986-12-19|1994-02-16|Sankyo Company Limited|New renin-inhibitory oligopeptides, their preparaton and their use|

NZ222755A|1986-12-23|1989-11-28|Warner Lambert Co|Renin inhibiting acyl peptide derivatives containing two to four amino acid residues, and pharmaceutical compositions|

US5024994A|1986-12-23|1991-06-18|Warner-Lambert Company|Renin inhibitors IV|

US4804743A|1987-01-29|1989-02-14|Warner-Lambert Copmany|Proline-containing renin inhibitors|

US4863905A|1987-02-04|1989-09-05|Warner-Lambert Company|Renin inhibitors II|

JPH03500880A|1987-10-26|1991-02-28|

US5063207A|1987-10-26|1991-11-05|Warner-Lambert Company|Renin inhibitors, method for using them, and compositions containing them|

US5162527A|1987-10-26|1992-11-10|Warner-Lambert Company|Renin inhibitors, processes for preparing them, methods for using them, and compositions containing them|

US5036054A|1988-02-11|1991-07-30|Warner-Lambert Company|Renin inhibitors containing alpha-heteroatom amino acids|

CA2004846A1|1988-12-19|1990-06-19|Yutaka Koike|N-substituted acylamino acid compounds, process for their production and their use|

US5106835A|1988-12-27|1992-04-21|American Cyanamid Company|Renin inhibitors|

EP0383635B1|1989-02-16|1995-07-12|Sankyo Company Limited|Peptides having renin inhibitory activity their preparation and use|

EP0569487A4|1991-01-31|1994-04-27|Abbott Laboratories|

US5227401A|1991-10-29|1993-07-13|G. D. Searle & Co.|Ethynyl alanine amino diol compounds for treatment of hypertension|

US5223535A|1991-10-29|1993-06-29|G. D. Searle & Co.|Propargyl glycine amino propargyl diol compounds for treatment of hypertension|

EP0539976A1|1991-10-29|1993-05-05|G.D. Searle & Co.|Ethynyl-alanine-amino-diol compounds for treatment of hypertension|

US5330996A|1991-10-29|1994-07-19|G. D. Searle & Co.|Amino acyl amino propargyl diol compounds for treatment of hypertension|

US5317039A|1992-07-20|1994-05-31|G. D. Searle & Co.|Cyclopropyl-alanine aryl/alkylsulfide/sulfonyl-terminated amino-diol compounds for treatment of hypertension|

US5268391A|1992-07-20|1993-12-07|C. D. Searle & Co.|Propargyl-terminated cycloalkylalkyl-P2-site substituted aryl/alkylsulfonyl-terminated alanine amino-diol compounds for treatment of hypertension|

US5314920A|1992-07-20|1994-05-24|G. D. Searle & Co.|Ethynyl-alanine aryl/alkylsulfonyl-terminated amino-diol compounds for treatment of hypertension|

US5246969A|1992-07-20|1993-09-21|G. D. Searle & Co.|Di-propargyl-containing aryl/alkylsulfonyl-terminated alanine amino-diol compounds for treatment of hypertension|

US5252591A|1992-08-14|1993-10-12|G. D. Searle & Company|Pyridinyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension|

US5212185A|1992-08-14|1993-05-18|G. D. Searle & Co.|Piperidinyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension|

US5373017A|1992-08-14|1994-12-13|G. D. Searle & Co.|Imidazolyl/benzimidazolyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension|

US5298505A|1992-08-14|1994-03-29|G. D. Searle & Co.|Ethynyl alanine amino diol compounds having a piperazinyl-terminated group or a piperazinyl-alkylamino-terminated group for treatment of hypertension|

US5422349A|1992-08-14|1995-06-06|G. D. Seale & Co.|Morpholino-oxazinyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension|

US5312838A|1992-09-21|1994-05-17|G. D. Searle & Co.|β-alanineamide aryl/alkylsulfide/sulfonyl-terminated amino-diol compounds for treatment of hypertension|

US5414018A|1993-09-24|1995-05-09|G. D. Searle & Co.|Alkylaminoalkyl-terminated sulfide/sulfonyl-containing propargyl amino-diol compounds for treatment of hypertension|

US5416119A|1993-10-25|1995-05-16|G. D. Searle & Co.|Alkylaminoalkyl-terminated sulfide/sulfonyl-containing cycloalkyl-alanine amino-diol compounds for treatment of hypertension|

US5432201A|1993-11-22|1995-07-11|G. D. Searle & Co.|Alkylaminoalkyl-sulfonyl-terminated β-alanineamide amino-diol compounds for treatment of hypertension|

US5508466A|1994-04-13|1996-04-16|G.D. Searle & Co.|Synthesis of N-protected-α-substituted-glycine racemic esters by zinc-mediated addition of organic halide to glycine cation equivalent|

US5780494A|1994-11-14|1998-07-14|G. D. Searle & Co.|Piperidinyl-terminated alkylamino ethynl alanine amino diol compounds for treatment of hypertension|

BR112014016548A8|2012-01-06|2017-07-04|Board Of Regents Of The Univ Of Oklahoma|sulfoxide based surfactants|

US10584306B2|2017-08-11|2020-03-10|Board Of Regents Of The University Of Oklahoma|Surfactant microemulsions|

法律状态:

优先权:

申请号 | 申请日 | 专利标题

JP25287884|1984-11-30|

JP26803584|1984-12-19|

JP1517785|1985-01-29|

[返回顶部]